CV Lattes
GoogleMyCitations
ORCID
Secretaria da Saúde (São Paulo - Estado). Coordenadoria de Serviços de Saúde (CSS). Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP) (Institutional affiliation for the last research proposal) Birthplace: Estados Unidos
Bachelor?s degree in Biochemistry/Molecular Biology University of California, Santa Barbara (1989) and doctorate in Molecular Pathology University of California, San Diego (1997). Obtained the title of Livre Docente (2011) Department of Radiology, in the area of Basic Oncology, FMUSP. Currently is a Medical Research Coordinator and director of the Viral Vector Laboratory in the Center of Translational Investigation in Oncology (CTO), Cancer Institute of Sao Paulo (ICESP). Also is a member of the Nucleus for the Convergence of Life Sciences, Physics and Engineering for Innovation in Diagnostics and Therapies (NAP IDx&T) as well as a member of the International Committee of the American Society of Gene and Cell Therapy. Has experience in the area of Biochemistry and Molecular Biology, with emphasis in Gene Therapy, acting principally in the following topics: viral vectors; tumor suppressor genes; immune modulating genes; cancer; genetic modification of stem cells; cardiovascular and hematopoietic diseases; animal models. (Source: Lattes Curriculum)
The burden of cancer on patient care and public health systems continues to grow, in part due to the aging population. Effective treatment for cancer is often not available, though new and improved approaches are being developed. Gene therapy has been in clinical use for over 25 years and its use for the treatment of cancer has shown several successes, including recent approval by the FDA…
Melanoma is an especially difficult tumor to treat once it has metastasized. Traditional approaches, such as chemotherapy with dacarbazine, are limited in their efficacy while newer drugs, such as vemurafanib (B-Raf inhibitor), are associated with acquired resistance to therapy. However, since 90% of melanomas retain wild-type p53, we propose this genotype may provide advantages that favo…
Retroviral vectors (and in particular, those derived from the Moloney Murine Leukemia Virus, MoMLV) are among the principle vectors utilized in gene therapy clinical trials, including the treatment of hematopoietic diseases such as Xl-SCID. Though the treatment of this disease was quite successful, some patients presented leukemia that was attributed to clonal proliferation that resulted …
(Only some records are available in English at this moment)
Prostate cancer is among the most common cancers in men worldwide. Despite treatment options, patients with metastatic disease have a five-year survival rate of only 29%, so development of new therapeutic strategies is needed in order to achieve long-term benefits. Treatment resistance mechanisms such as tumor heterogeneity and an immunosuppressive microenvironment prevent the establishme…
The immune system functions include regulation by immune checkpoints (ICPs) - pathways that either inhibit or activate the immune cells, mainly T lymphocytes. Cancer cells and Antigen Presenting Cells (APCs) found in the tumor microenvironment can express ICPs with different patterns, thus diminishing the immune response to the disease. Blocking the cytotoxic T-lymphocyte associated prote…
Melanoma is the most aggressive type of skin cancer and has a high lethality. A growing number of works have shown the relevance and benefits of gene therapy in treating cancer, including melanoma. In this context, recent research points to vaccination involving neoantigens as a promising strategy in the treatment of this malignancy. Previous results from the research group conducted by P…
(Only some records are available in English at this moment)
Although metastatic melanoma is the least prevalent among skin cancers, it is the most lethal due to resistance to currently available treatments. Therefore, new effective therapeutic approaches are urgently needed. An interesting feature of melanoma is the presence of wild-type p53 protein, which in spite of being inactive represents an important therapeutic target since its modulation m…
Melanoma has high mortality and significant impact on society. Tumors are not simply masses of cancer cells, they are complex "organs" with a variety of cell types and structures that cooperate with tumor progression. Alternative therapies, such as gene therapy, are showing promising results in preclinical and clinical research. Our laboratory developed viral vectors carrying INF-² that o…
Between 1979-1980, several laboratories identified and characterized viral genes, whose products would be sufficient to immortalize and transform mammal cell lines, which led to a simplistic vision in which cancer would be a genetic disease, conferring cellular autonomy. In the beginning of the XXI century, the idea that cancer was a more complex pathology became completely accepted. Desp…
(Only some records are available in English at this moment)
Colorectal cancer remains a challenge despite recent advances in treatment. It is the third most common carcinoma and the second cause of cancer related death. There is a plethora of genetic alterations linked to development and progression of colorectal cancer, though these varied phenotypes are unified by disruption in the balance between tumor suppressor and oncogenic pathways, often i…
Among the current strategies to use the immune system to treat cancer patients, the blockade of immune checkpoints has yielded highly encouraging results in several clinical trials. Recent work in Dr. Schreiber`s laboratory has used a combination of next generations sequencing, bioinformatics and state-of-the-art immunology techniques to shown that tumor specific T cells reactivated upon …
| 1 / 1 | Ongoing research grants |
| 9 / 4 | Completed research grants |
| 5 / 5 | Ongoing scholarships in Brazil |
| 24 / 14 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 41 / 26 | All research grants and scholarships |
| Associated processes | |
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
| Publications | 20 |
| Citations | 90 |
| Cit./Article | 4.5 |
| Data from Web of Science | |
STRAUSS‚ B.E.; COSTANZI-STRAUSS‚ E.. pCLPG: a p53-driven retroviral system. VIROLOGY, v. 321, n. 2, p. 165-172, 2004. (00/12156-5)
MEDRANO, RUAN F. V.; HUNGER, ALINE; CATANI, JOAO P. P.; STRAUSS, BRYAN E.. Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-beta gene transfer to cancer cells: An inducer of immunogenic cell death. ONCOIMMUNOLOGY, v. 6, n. 7, 2017. Web of Science Citations: 2. (11/10656-5, 13/09474-5, 13/25167-5, 15/26580-9)
TAMURA, RODRIGO ESAKI; HUNGER, ALINE; FERNANDES, DENISE C.; LAURINDO, FRANCISCO R.; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector. Human Gene Therapy, v. 28, n. 8, p. 639-653, AUG 2017. Web of Science Citations: 3. (13/25167-5, 11/21256-8)
PORTELA CATANI, JOAO PAULO; MEDRANO, RUAN F. V.; HUNGER, ALINE; DEL VALLE, PAULO; ADJEMIAN, SANDY; ZANATTA, DANIELA BERTOLINI; KROEMER, GUIDO; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Intratumoral Immunization by p19Arf and Interferon-beta Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. TRANSLATIONAL ONCOLOGY, v. 9, n. 6, p. 565-574, DEC 2016. Web of Science Citations: 8. (13/09474-5, 13/25167-5, 12/25380-8, 14/11524-3, 11/10656-5)
CHICAYBAM, LEONARDO; BONAMINO, MARTIN H.; LUCKOW INVITTI, ADRIANA; BORTMAN ROZENCHAN, PATRICIA; DE LUNA VIEIRA, IGOR; STRAUSS, BRYAN E.. Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. CANCERS, v. 12, n. 9, SEP 2020. Web of Science Citations: 0. (15/26580-9)
FRATINI, PAULA; STRAUSS, BRYAN E.. Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector. VIROLOGY JOURNAL, v. 7, JAN 22 2010. Web of Science Citations: 0. (00/12156-5)
DEL VALLE, PAULO ROBERTO; MENDONCA, SAMIR ANDRADE; ANTUNES, FERNANDA; HUNGER, ALINE; TAMURA, RODRIGO E.; ZANATTA, DANIELA BERTOLINI; STRAUSS, BRYAN E.. Exploration of p53 plus interferon-beta gene transfer for the sensitization of human colorectal cancer cell lines to cell death. CANCER BIOLOGY & THERAPY, APR 2021. Web of Science Citations: 0. (15/26580-9)
VIEIRA, IGOR DE LUNA; TAMURA, RODRIGO ESAKI; HUNGER, ALINE; STRAUSS, BRYAN E.. Distinct Roles of Direct Transduction Versus Exposure to the Tumor Secretome on Murine Endothelial Cells After Melanoma Gene Therapy with Interferon-beta and p19Arf. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, v. 39, n. 4, p. 246-258, APR 1 2019. Web of Science Citations: 0. (13/25167-5, 11/10656-5, 11/21256-8, 15/26580-9)
HUNGER, ALINE; MEDRANO, V, RUAN F.; ZANATTA, DANIELA B.; DEL VALLE, PAULO R.; MERKEL, CHRISTIAN A.; SALLES, THIAGO DE ALMEIDA; FERRARI, DANIEL G.; FURUYA, TATIANE K.; BUSTOS, SILVINA O.; SAITO, RENATA DE FREITAS; et al. Reestablishment of p53/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. CELL DEATH DISCOVERY, v. 3, 2017. Web of Science Citations: 7. (13/09474-5, 13/25167-5, 11/10656-5)
STRAUSS, BRYAN E.; OLIVEIRA SILVA, GISSELE ROLEMBERG; VIEIRA, IGOR DE LUNA; DUTRA CERQUEIRA, OTTO LUIZ; DEL VALLE, PAULO ROBERTO; VIEIRA MEDRANO, RUAN FELIPE; MENDONCA, SAMIR ANDRADE. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics, v. 73, n. 1, 2018. Web of Science Citations: 0. (12/05066-7, 16/18197-3, 13/09474-5, 13/25167-5, 13/16074-3, 15/26580-9)
TAMURA, RODRIGO ESAKI; DA SILVA SOARES, RAFAEL BENTO; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy. CANCER BIOLOGY & THERAPY, v. 17, n. 12, p. 1221-1230, 2016. Web of Science Citations: 5. (13/25167-5, 11/21256-8)
ZANATTA, DANIELA B.; TSUJITA, MARISTELA; BORELLI, PRIMAVERA; AGUIAR, RODRIGO B.; FERRARI, DANIEL G.; STRAUSS, BRYAN E.. Genetic barcode sequencing for screening altered population dynamics of hematopoietic stem cells transduced with lentivirus. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, v. 1, 2014. Web of Science Citations: 1. (13/25167-5, 09/51386-0, 14/03205-5)
B.E. STRAUSS; E. COSTANZI-STRAUSS. Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency. Brazilian Journal of Medical and Biological Research, v. 40, n. 5, p. 601-613, Maio 2007. (00/12156-5)
VIEIRA MEDRANO, RUAN FELIPE; PORTELA CATANI, JOAO PAULO; RIBEIRO, ALINE HUNGER; TOMAZ, SAMANTA LOPES; MERKEL, CHRISTIAN A.; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy. CANCER IMMUNOLOGY IMMUNOTHERAPY, v. 65, n. 4, p. 371-382, APR 2016. Web of Science Citations: 9. (13/09474-5, 13/25167-5, 14/11524-3, 11/10656-5)
STRAUSS‚ B.E.; BAJGELMAN‚ M.C.; COSTANZI-STRAUSS‚ E.. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Therapy, v. 12, n. 12, p. 935-946, 2005. (00/12156-5)
MERKEL, C. A.; MEDRANO, R. F. V.; BARAUNA, V. G.; STRAUSS, B. E.. Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Therapy, v. 20, n. 5, p. 317-325, MAY 2013. Web of Science Citations: 12. (10/03958-2)
STRAUSS‚ B.E.; COSTANZI-STRAUSS‚ E.. pCLPG: a p53-driven retroviral system. VIROLOGY, v. 321, n. 2, p. 165-172, 2004. (00/12156-5)
MEDRANO, RUAN F. V.; HUNGER, ALINE; CATANI, JOAO P. P.; STRAUSS, BRYAN E.. Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-beta gene transfer to cancer cells: An inducer of immunogenic cell death. ONCOIMMUNOLOGY, v. 6, n. 7, 2017. Web of Science Citations: 2. (11/10656-5, 13/09474-5, 13/25167-5, 15/26580-9)
TAMURA, RODRIGO ESAKI; HUNGER, ALINE; FERNANDES, DENISE C.; LAURINDO, FRANCISCO R.; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector. Human Gene Therapy, v. 28, n. 8, p. 639-653, AUG 2017. Web of Science Citations: 3. (13/25167-5, 11/21256-8)
PORTELA CATANI, JOAO PAULO; MEDRANO, RUAN F. V.; HUNGER, ALINE; DEL VALLE, PAULO; ADJEMIAN, SANDY; ZANATTA, DANIELA BERTOLINI; KROEMER, GUIDO; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Intratumoral Immunization by p19Arf and Interferon-beta Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. TRANSLATIONAL ONCOLOGY, v. 9, n. 6, p. 565-574, DEC 2016. Web of Science Citations: 8. (13/09474-5, 13/25167-5, 12/25380-8, 14/11524-3, 11/10656-5)
MEDRANO, RUAN F. V.; HUNGER, ALINE; CATANI, JOAO P. P.; STRAUSS, BRYAN E.. Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-beta gene transfer to cancer cells: An inducer of immunogenic cell death. ONCOIMMUNOLOGY, v. 6, n. 7, 2017. Web of Science Citations: 2. (15/26580-9, 13/09474-5, 13/25167-5, 11/10656-5)
TAMURA, RODRIGO ESAKI; HUNGER, ALINE; FERNANDES, DENISE C.; LAURINDO, FRANCISCO R.; COSTANZI-STRAUSS, EUGENIA; STRAUSS, BRYAN E.. Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector. Human Gene Therapy, v. 28, n. 8, p. 639-653, AUG 2017. Web of Science Citations: 3. (13/25167-5, 11/21256-8)
CHICAYBAM, LEONARDO; BONAMINO, MARTIN H.; LUCKOW INVITTI, ADRIANA; BORTMAN ROZENCHAN, PATRICIA; DE LUNA VIEIRA, IGOR; STRAUSS, BRYAN E.. Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. CANCERS, v. 12, n. 9, SEP 2020. Web of Science Citations: 0. (15/26580-9)
CÓDIGO DE BARRAS GENÉTICO PI1003468-4 - Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Universidade de São Paulo (USP). Bryan Eric Strauss; Daniela Bertolini Zanatta - September 2010, 01
VETOR BICISTRÔNICO, PROCESSO DE OBTENÇÃO DO VETOR BICISTRÔNICO, USO DO VETOR BICISTRÔNICO PARA PREPARAÇÃO DE MEDICAMENTO PARA TERAPIA GÊNICA; COMPOSIÇÃO FARMACÊUTICA E USO DO VETOR BICISTRÔNICO EM TERAPIA GÊNICA PI1010481-0 - Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Universidade de São Paulo (USP). Bryan Eric Strauss - April 2010, 16
VETOR PARA EXPRESSÃO DE VEGF COM EXPRESSÃO REGULADA POR P53 E USOS DO MESMO PI1103671-0 - Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Universidade de São Paulo (USP). Bryan Eric Strauss; José Eduardo Krieger; Marcio Chaim Bajgelman; Leonardo Dos Santos - July 2011, 27